We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Acceptability of the reusable SurePal™ selfinjection device for Omnitrope® among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational study.
- Authors
Partsch, Carl-Joachim; Schnabel, Dirk; Ehtisham, Sarah; Johnstone, Helen C.; Zabransky, Markus; Kiess, Wieland
- Abstract
Background: SurePal™ is a reusable self-injection system that has been developed to support daily administration of Omnitrope® (Sandoz, Kundl, Austria). A questionnaire-based crosssectional survey was conducted to evaluate acceptability of, and preference for, SurePal™ in pediatric patients who were prescribed treatment with Omnitrope® within routine clinical care. Methods: This multicenter, observational study was incorporated into the ongoing non- interventional PATRO (PAtients TReated with Omnitrope®) Children study. Patients (or caregivers) were provided with a questionnaire that included five main topics; attractiveness of the device, training received, using SurePal™, the low drug wastage system, and experience versus other devices used previously (where applicable). Questions were scored on a 5-point scale, with -2 being the worst possible outcome (eg, very hard/very poor) and 2 being the best possible outcome (eg, very easy/excellent). Results: A total of 186 patients were included in this study (Germany, n=154; UK, n=32). The attractiveness of SurePal™ was rated as excellent/good by 87.1% of patients. Overall, 86.5% of patients found that using their SurePal™ was very easy/easy. Almost all patients (96.2%) found that preparing their SurePal™ for injection was very easy/easy, and 89.2% found that injecting with SurePal™ was very easy/easy. 85.5% of patients recorded that the dose memory function was helpful, and 87.6% that taking their SurePal™ apart after an injection was very easy/easy. Of the 88 patients who recorded that they had used the low drug waste feature, 89.8% found the feature to be helpful. Among pre-treated patients (n=42), 81% recorded that SurePal™ was much better/better than their previously used device. Conclusion: This questionnaire-based cross-sectional survey in pediatric patients confirms the ease of use and patient preference for SurePal™, a reusable self-injection system that has been developed to support daily administration of Omnitrope®.
- Subjects
SELF-monitoring (Psychology); SOMATOTROPIN; CHILD care; PATIENT compliance; DRUG administration; CROSS-sectional method
- Publication
Medical Devices: Evidence & Research, 2015, Vol 8, p389
- ISSN
1179-1470
- Publication type
Article
- DOI
10.2147/MDER.S93209